A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis
Background: Ublituximab, a novel monoclonal antibody (mAb) targeting a unique epitope on the CD20 antigen, is glycoengineered for enhanced B-cell targeting through antibody-dependent cellular cytotoxicity (ADCC). Greater ADCC may allow lower doses and shorter infusion times versus other anti-CD20 mA...
保存先:
| 主要な著者: | , , , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | 英語 |
| 出版事項: |
2020
|
| オンライン･アクセス: | https://doi.org/10.1177/1352458520918375 https://journals.sagepub.com/doi/pdf/10.1177/1352458520918375 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|